The oral route for the administration of cytotoxic drugs: Strategies to increase the efficiency and consistency of drug delivery

Investigational New Drugs

Volumn 18, Issue 3, 2000, Pages 231-241

  Bardelmeijer, Heleen A ^a   Van Tellingen, Olaf ^a   Schellens, Jan H M ^a,b   Beijnen, Jos H ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Bioavailability; CYP3A; Cytotoxic drugs; Oral administration; P glycoprotein; Variability

Indexed keywords

CYTOCHROME P450 ISOENZYME; CYTOTOXIC AGENT; GLYCOPROTEIN P; METHYLXANTHINE; SALICYLIC ACID; SURFACTANT;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TRANSPORT; GASTROINTESTINAL TOXICITY; HUMAN; LIVER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INTESTINAL ABSORPTION; MIXED FUNCTION OXYGENASES; P-GLYCOPROTEIN;

EID: 0033894569     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006469621561     Document Type: Review

References (118)

1. Demario MD, Ratain MJ: Oral chemotherapy: Rationale and future directions. J Clin Oncol 16: 2557-2567, 1998
2. Hoff PM, Pazdur R, Benner SE, Canetta R: UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 9: 479-490, 1998
3. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996
4. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T: Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 16: 1795-1802, 1998
5. McKeage MJ, Mistry P, Ward J, Boxall FE, Loh S, O'Neill C, Ellis P, Kelland LR, Morgan SE, Murrer B, Santabarbara P, Harrap KR, Judson IR: A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 36: 451-458, 1995
6. Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110-115, 1997
7. Kakolyris S, Samonis G, Koukourakis M, Vlachonicolis I, Chalkiadakis G, Kalbakis K, Souglakos I, Agelaki S, Toloudis P, Georgoulias V: Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am J Clin Oncol 21: 505-508, 1998
8. Gridelli C, Rossi A, Scognamiglio F, Guida C, Fiore F, Gatani T, Scoppa G, Pergola M: Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study. Anticancer Res 17: 4755-4758, 1997
9. Sullivan SD, Mozaffari E, Johnson ES, Wolitz R, Follansbee SE: An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients. Clin Ther 18: 546-558, 1996
10. Hellriegel ET, Bjornsson TD, Hauck WW: Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 60: 601-607, 1996
11. Urquhart J: Patient compliance with crucial drug regimens: implications for prostate cancer. Eur Urol 29: Suppl 2: 124-131, 1996
12. Davies HA, Lilleyman JS: Compliance with oral chemotherapy in childhood lymphoblastic leukaemia. Cancer Treat Rev 21: 93-103, 1995
13. Macheras P, Reppas C, Dressman JB: Biopharmaceutics of orally administered drugs. 1st edition, Ellis Horwood, 1995
14. Rowland M, Tozer TN: Clinical parmacokinetics: Concepts and applications. 3rd edition. Baltimore, Williams and Wilkins, 1995
15. Kararli TT: Gastro intestinal absorption of drugs. Crit Rev Ther Drug Carrier Syst 6: 39-86, 1989
16. Rang HP, Dale MM: Pharmacology. 3rd edition. Churchill Livingstone, 1995
17. Hartman NR, Yarchoan R, Pluda JM, Thomas RV, Wyvill KM, Flora KP, Broder S, Johns DG: Pharmacokinetics of 2′,3′-dideoxyninosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications. Clin Pharmacol Ther 50: 278-285, 1991
18. Williams L, Hill DP, Jr., Davis JA, Lowenthal DT: The influence of food on the absorption and metabolism of drugs: an update. Eur J Drug Metab Pharmacokinet 21: 201-211, 1996
19. Hoetelmans RM, Meenhorst PL, Mulder JW, Burger DM, Koks CH, Beijnen JH: Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci 19: 159-175, 1997
20. Tsuji A, Tamai I: Carrier-mediated intestinal transport of drugs. Pharm Res 13: 963-977, 1996
21. Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162, 1976
22. Endicott JA, Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171, 1989
23. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993
24. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug- resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735-7738, 1987
25. Lankas GR, Cartwright ME, Umbenhauer D: P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 143: 357-365, 1997
26. Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR: Placental P-glycoprotein defiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol 12: 457-463, 1998
27. Schinkel AH, Smit JJM, Van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P: Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502, 1994
28. Schinkel AH, Mayer U, Wagenaar E, Mol CAAM, van Deemter L, Smit JJM, van der Valk MA, Voordouw AC, Spits H, Van Tellingen O, Zijlmans JM, Fibbe WE, Borst P: Normal viability and altered pharmacokinetics in mice lacking mdrl-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94: 4028-4033, 1997
29. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O: Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94: 2031-2035, 1997
30. Back DJ, Rogers SM: Review: first-pass metabolism by the gastrointestinal mucosa. Aliment Pharmacol Ther 1: 339-357, 1987
31. Kolars JC, Awni WM, Merion RM, Watkins PB: First-pass metabolism of cyclosporin by the gut. Lancet 338: 1488-1490, 1991
32. Webber IR, Peters WHM, Back DJ: Cyclosporin metabolism by human gastrointestinal mucosal microsomes. Br J Clin Pharmacol 33: 661-664, 1992
33. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ: The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58: 15-19, 1995
34. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB: Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90: 1871-1878, 1992
35. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, Watkins PB: CYP3A gene expression in human gut epithelium. Pharmacogenetics 4: 247-259, 1994
36. Krishna DR, Klotz U: Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26: 144-160, 1994
37. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283: 1552-1562, 1997
38. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 22: 947-955, 1994
39. Guengerich FP: Characterization of human cytochrome P450 enzymes. FASEB J 6: 745-748, 1992
40. Wacher VJ, Wu CY, Benet LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13: 129-134, 1995
41. Zeller FP, Ueda CT, Wulf BG, Meyers DG: Effect of caffeine on the oral absorption and disposition of quinidine. Clin Pharm 3: 72-75, 1984
42. Nakamura J, Takamura R, Kimura T, Muranishi S, Sezaki H: Enhancement effect of methylxanthines on the intestinal absorption of poorly absorbable dyes from the rat small intestine. Biochem Pharmacol 28: 2957-2960, 1979
43. Whitmore DA, Brookes LG, Wheeler KP: Relative effects of different surfactants on intestinal absorption and the release of proteins and phospholipids from the tissue. J Pharm Pharmacol 31: 277-283, 1979
44. Benet LZ, Wu CY, Hebert MF, Wacher VJ: Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J Contr Release 39: 139-143, 1996
45. Berg SL, Tolcher A, O'Shaughnessy JA, Denicoff AM, Noone M, Ognibene FP, Cowan KH, Balis FM: Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol 13: 2039-2042, 1995
46. Wishart GC, Bissett D, Paul J, Jodrell D, Harnett A, Habeshaw T, Kerr DJ, Macham MA, Soukop M, Leonard RCF, Knepil J, Kaye SB: Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol 12: 1771-1777, 1994
47. Solary E, Caillot D, Chauffert B, Casasnovas RO, Dumas M, Maynadie M, Guy H: Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 10: 1730-1736, 1992
48. van der Graaf WTA, de Vries EGE, Uges DRA, Nanninga AG, Meijer C, Vellenga E, Mulder POM, Mulder NH: In vitro and in vivo modulation of multidrug resistance with amiodarone. Int J Cancer 48: 616-622, 1991
49. Ferry DR, Traunecker H, Kerr DJ: Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A: 1070-1081, 1996
50. Toffoli G, Sorio R, Gigante M, Corona G, Galligioni E, Boiocchi M: Cyclosporin A as a multi drug-resistant modulator in patients with renal cell carcinoma treated with teniposide. Br J Cancer 75: 715-721, 1997
51. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F: In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51: 4226-4233, 1991
52. Covelli A: SDZ PSC 833: A new multidrug-resistance modulator. Tumori 83: S21-S24, 1997
53. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T: In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53: 4595-4602, 1993
54. Booth CL, Brouwer KR, Brouwer KLR; Effect of multidrug resistance modulators on the hepatobillary disposition of doxorubicin in the isolated perfused rat liver. Cancer Res 58: 3641-3648, 1998
55. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ: Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56: 4171-4179, 1996
56. Starling JJ, Shepard RL, Cao J, Law KL, Norman BH, Kroin JS, Ehlhardt WJ, Baughman TM, Winter MA, Bell MG, Shih C. Gruber J, Elmquist WF, Dantzig AH: Pharmacological characterization of LY335979: a potent cyclopropyldiben-zosuberane modulator of P-glycoprotein. Adv Enzyme Regul 37: 335-347, 1997
57. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268: 6077-6080, 1993
58. Spoelstra EC, Westerhoff HV, Pinedo HM, Dekker H, Lankelma J: The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate. Eur J Biochem 221: 363-373, 1994
59. Archinal-Mattheis A, Rzepka RW, Watanabe T, Kokubu N, Itoh Y, Combates NJ, Bair KW, Cohen D: Analysis of the interactions of SDZ PSC 833 ([3′-keto-Bmt1]Val2]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol Res 7: 603-610, 1995
60. Twentyman PR, Bleehen NM: Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 27: 1639-1642, 1991
61. Smith AJ, Mayer U, Schinkel AH, Borst P: Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. J Nat Cancer Inst 90: 1161-1166, 1998
62. Jette L, Murphy GF, Beliveau R: Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC 833 treatment. Int J Cancer 76: 729-737, 1998
63. van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, Beijnen JH: Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 76: 1181-1183, 1997
64. van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH: Enhanced oral absorption and decreased elimination of paclitaxel in mice with cyclosporin A. Clin Cancer Res 4: 2293-2297, 1998
65. Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM: Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54: 4026-4035, 1994
66. Meerum Terwogt JM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Schellens JHM: Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 352: 285, 1998
67. Malingré MM, Schellens JHM, Duchin K, Rosing H, Beijnen JH: Oral paclitaxel in a twice daily dose regimen. Br J Clin Pharmacol 47: 463P, 1999
68. Malingré MM, Meerum Terwogt JM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, ten Bokkel Huinink WW, Swart M, Duchin K, Schellens JHM: Clinical pharmacology of oral paclitaxel in a dose escalating study. Proc Am Soc Clin Oncol 18: 166a, 1999
69. Meerum Terwogt JM, Malingré MM, Beijnen JH, van Tellingen O, Rosing H, Koopman FJ, ten Bokkel Huinink WW, Swart M, Duchin K, Schellens JHM: Mass balance of paclitaxel (Paxene) in humans after both intravenous and oral administration. Proc Am Soc Clin Oncol 18: 190a, 1999
70. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Racissi S, Hidalgo IJ, Scherman D: Polarized transport of docetaxel and vinblastine mediated by P-glycoprotcin in human intestinal epithelial cell monolayers. Biochem Pharmacol 48: 1528-1530, 1994
71. Richel DJ, Malingre MM, ten Bokkel Huinink WW, Rosing H. van Tellingen O, Swart M, Beijnen JH, Schellens JHM: Cyclosporin A strongly enhances the oral bioavailability of docetaxel in cancer patients. Proc Am Soc Clin Oncol 18: 201a, 1999
72. D'Incalci M, Farina P, Sessa C, Mangioni C, Conter V, Masera G, Rocchetti M, Pisoni MB, Piazza E, Beer M, Cavalli F: Pharmacokinetics of VP 16-213 given by different administration methods. Cancer Chemother Pharmacol 7: 141-145, 1982
73. Smyth RD, Pfeffer M, Scalzo A, Comis RL: Bioavailability and pharmacokinetics of etoposide (VP-16). Semin Oncol 12, Suppl 2: 48-51, 1985
74. Harvey VJ, Slevin ML, Joel SP, Smythe MM, Johnston A, Wrigley PFM: Variable bioavailability following repeated oral doses of etoposide. Eur J Cancer Clin Oncol 21: 1315-1319, 1985
75. Desoize B, Woirin V, Legros M, Coninx P. Reduced oral etoposide bioavailability in patients with advanced cancer of the head and neck. J Natl Cancer Inst 84: 348-350, 1992
76. Nguyen L, Chatelut E, Chevreau C, Tranchand B, Lochon I, Bachaud JM, Pujol A, Houin G, Bugat R, Canal P: Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol 41: 125-132, 1998
77. Harvey VJ, Slevin NIL, Joel SP, Johnston A, Wrigley PFM: The effect of dose on the bioavailability of oral etoposide. Cancer Chemother Pharmacol 16: 178-181, 1986
78. Slevin ML, Joel SP, Whomsley R, Devenport K, Harvey VJ, Osborne RJ, Wrigley PFM: The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation. Cancer Chemother Pharmacol 24: 329-331, 1989
79. Hande KR, Krozely MG, Greco FA, Hainsworth JD, Johnson DH: Bioavailability of low-dose oral etoposide. J Clin Oncol 11: 374-377, 1993
80. Greco FA: Chronic etoposide administration: overview of clinical experience. Cancer Treat Rev 19, Suppl C: 35-45, 1993
81. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI: Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10: 1635-1642, 1992
82. Keller RP, Altermatt HJ, Donatsch P, Zihlmann H, Laissue JA, Hiestand PC: Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int J Cancer 51: 433-438, 1992
83. Leu BL, Huang JD: Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 35: 432-436, 1995
84. Kobayashi K, Ratain MJ, Fleming GF, Vogelzang NJ, Cooper N, Sun BL: A phase I study of CYP3A4 modulation of oral etoposide with ketoconazoleconazol in patients with advanced cancer. Proc Am Soc Clin Oncol 15: 471, 1996
85. Shepard DR, Kobayashi K, Wang C, Ratain MJ: Population pharmacokinetic determination of the modulation of oral etoposide (VP-16) elimination by ketoconazole. Proc Am Soc Clin Oncol 17: 190a, 1998
86. Siegsmund MJ, Cardarelli C, Aksentijevich I, Sugimoto Y, Pastan I, Gottesman MM: Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urol 151: 485-491, 1994
87. Stewart DJ, Grewaal D, Green RM, Verma S, Maroun JA, Redmond D, Robillard L, Gupta S: Bioavailability and pharmacology of oral idarubecin. Cancer Chermother Pharmacol 27: 308-314, 1991
88. Schleyer E, Kuhn S, Ruhrs H, Unterhalt M, Kaufmann CC, Kern W, Braess J, Straubel G, Hiddemann W: Oral idarubicin pharmacokinetics - correlation of trough level with idarubicin area under curve. Leukemia 10: 707-712, 1996
89. Damiani D, Michieli M, Michelutti A, Pea F, Baraldo M, Fanin R, Russo D, Furlanut M, Baccarani M: P170-related multidrug resistance. Enhancement of idarubicin content in leukemic cells with cyclosporin in vivo: a report of two cases. Leukemia 9: 1792-1795, 1995
90. Tolomeo M, Gancitano RA, Musso M, Porretto F, Perricone R, Abbadessa V, Cajozzo A: Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells. Cancer Chemother Pharmacol 39: 157-161, 1996
91. Tidefelt U, Prenkert M, Paul C: Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrugresistant HL60 cells. Cancer Chemother Pharmacol 38: 476-480, 1996
92. Hegewisch-Becker S: MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Leukemia 10, Suppl 3: S32-S38, 1996
93. Armand JP, Marty M: Navelbine: a new step in cancer therapy? Semin Oncol 2: 41-45, 1989
94. Zhou XJ, Bore P, Monjanel S, Sahnoun Z, Favre R, Durand A, Rahinani R: Pharmacokinetics of navelbine after oral administration in cancer patients. Cancer Chemother Pharmacol 29: 66-70, 1991
95. Ueda K, Cardarelli C, Gottesman MM, Pastan I: Expression of full-length DNA for the human MDR1 gene confers resistance to colchicine, doxorubicin and vinblastine. Proc Natl Acad Sci USA 84: 3004-3008, 1987
96. Meyers MB, Scotto KW, Sirotnak FM: P-glycoprotein content and mediation of vincristine efflux: correlation with the level of differentiation in luminal epithelium of mouse small intestine. Cancer Commun 3: 159-165, 1991
97. Zhou XJ, Zhou-Pan XR, Favre R, Rahmani R: Relative bioavailability of two oral formulations of navelbine in cancer patients. Biopharm Drug Dispos 15: 577-586, 1994
98. Lucas S, Donehower RC, Rowinsky EK, Trump DL, Weiner E, Wargin WA, Hohneker JA: Absolute bioavailability (ABA) and pharmacokinetics of weekly navelbine (NVB) liquid filled soft gelatin capsules at full therapeutic doses in patients (pts) with solid tumors. Proc 7th NIC-EORTC Symposium on New Drugs in Cancer Therapy abstract 264, March 17-20, 1992
99. van Tellingen O, Sips JHM, Beijnen JH, Bult A, Nooijen WJ: Pharmacology, bioanalysis and pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives. Anticancer Res 12: 1699-1716, 1992
100. Schellens JHM, Creemers GJ, Beijnen JH, Rosing H, de Boer-Dennert M, McDonald M, Davies B, Verweij J: Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 731: 1268-1271, 1996
101. Herben VMM, Schellens JH, ten Bokkel Huinink WW, Rosing H, van Zomeren DM, Batchelor FB, Beusenberg FB, Beijnen JH: The effect of food co-administration on the pharmacokinetics of topotecan gelatin capsules. Proc Am Soc Clin Oncol 17: 1999
102. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52: 2268-2278, 1992
103. Hoki Y, Fujimori A, Pommier Y: Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother Pharmacol 40: 433-438, 1997
104. Sugiyarna Y, Kato Y, Chu XY: Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother Pharmacol 42, Suppl: S44-9, 1998
105. Jansen WJM, Hulscher TM, van Ark-Otte J, Giaccone G, Pinedo HM, Boven E: CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. Br J Cancer 77: 359-365, 1998
106. Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16: 215-237, 1989
107. Finch RE, Bending MR, Lant AF: Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients. Br J Clin Pharmacol 7: 613-617, 1979
108. Cohen JL, Irwin LE, Marshall GJ, Darvey H, Bateman JR: Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893). Cancer Chemother Rep 58: 723-731, 1974
109. Chirstophidis N, Vajda FJ, Lucas I, Drummer O, Moon WJ, Louis WJ: Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokinet 3: 330-336, 1978
110. Naguib FN, el Kouni MH, Cha S: Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45: 5405-5412, 1985
111. Harris BE, Song R, Soong SJ, Diasio RB: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197-201, 1990
112. Spector T, Harrington JA, Porter DJ: 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 46: 2243-2248, 1993
113. Baccanari DP, Davis ST, Knick VC, Spector T: 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 90: 11064-11068, 1993
114. Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC, Grochow LB, Sartorius SE, Noe DA, Hohneker JA, Rowinsky EK: Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 14: 3085-3096, 1996
115. Pazdur R, Hoff PM, Medgyesy D, Royce M, Brito R: The oral fluorouracil prodrugs. Oncology (Huntingt) 12, Suppl 7: 48-51, 1998
116. Anttila MI, Sotaniemi EA, Kairaluoma MI, Mokka RE, Sundquist HT: Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol 10: 150-153, 1983
117. Fukushima M, Shimamoto Y, Kato T, Uchida J, Yonekura R, Ohshimo H, Shirasaka T: Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anticancer Drugs 9: 817-823, 1998
118. Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y, Ishitsuka H: Activation of 5′deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull (Tokyo) 31: 175-178, 1983